Piper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14
Piper Sandler analyst David Westenberg upgrades Neogen (NASDAQ:NEOG) from Neutral to Overweight and raises the price target from $13 to $14.
Read original at benzingaStocks · News reference
Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia
The Australian agency is conducting a Phase 2 assessment of Zoetis' $160 million acquisition of Neogen's genomics unit due to competition concerns.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 17, 2026, 1:57 PM
- Checked
- Jul 17, 2026, 1:57 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — NEOGEN CORP (NEOG)
Filed: 2026-08-07 AccNo: 0001193125-26-340216 Size: 144 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarPiper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13
Piper Sandler analyst David Westenberg reiterates Neogen (NASDAQ:NEOG) with a Neutral and raises the price target from $11 to $13.
Read original at benzingaNeogen shares are trading higher after the company reported better-than-expected Q4 financial results.
Read original at benzingaGlobal Veterinary Medical Devices Market to Reach $9.1 Billion by 2030, Driven by Rising Pet Ownership and Technological Innovation in Animal Healthcare
The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.
Read original at globenewswire-incTD Cowen Maintains Buy on Zoetis, Lowers Price Target to $94
TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $104 to $94.
Read original at benzinga